{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:19:18Z","timestamp":1794853158943,"version":"4.9.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS088248"],"award-info":[{"award-number":["NS088248"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004856","name":"New York State Department of Health","doi-asserted-by":"publisher","award":["GR500305"],"award-info":[{"award-number":["GR500305"]}],"id":[{"id":"10.13039\/100004856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009750","name":"Medical Center, University of Rochester","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.parkreldis.2020.10.020","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T21:27:02Z","timestamp":1602538022000},"page":"69-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability"],"prefix":"10.1016","volume":"81","author":[{"given":"Ruth B.","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Auinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Tarolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Iourinets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Cristina","family":"Gil-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene H.","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2020.10.020_bib1","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/mds.26643","article-title":"Prevalence of anxiety in Parkinson's disease: as systematic review and meta-analysis","volume":"31","author":"Broen","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.10.020_bib2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/mds.25664","article-title":"Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms","volume":"29","author":"Duncan","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.10.020_bib3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jagp.2012.10.023","article-title":"Pharmacologic treatment of anxiety disorders in Parkinson disease","volume":"21","author":"Pontone","year":"2013","journal-title":"Am. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.parkreldis.2020.10.020_bib4","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1212\/WNL.45.9.1757","article-title":"Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study","volume":"45","author":"Maricle","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.10.020_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/jnnp-2017-316193","article-title":"Serotonin transporter binding and anxiety symptoms in Parkinson's disease","volume":"89","author":"Joling","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.10.020_bib6","doi-asserted-by":"crossref","first-page":"111981","DOI":"10.1016\/j.bbr.2019.111981","article-title":"Anxiety-like behavior induced by 6-OHDA animal model of Parkinson's disease may be related to a dysregulation of neurotransmitter systems in brain areas related to anxiety","volume":"371","author":"Vieira","year":"2019","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.parkreldis.2020.10.020_bib7","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e3182516244","article-title":"A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease","volume":"78","author":"Richard","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.10.020_bib8","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","article-title":"A controlled trial of antidepressants in patients with Parkinson disease and depression","volume":"72","author":"Menza","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.10.020_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000118837","article-title":"Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies","volume":"25","author":"Gammans","year":"1992","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.parkreldis.2020.10.020_bib10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1440-1819.2009.02055.x","article-title":"Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder","volume":"64","author":"Mokhber","year":"2010","journal-title":"Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.parkreldis.2020.10.020_bib11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbr.2014.07.037","article-title":"Serotonin in Parkinson's disease","volume":"277","author":"Politis","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.parkreldis.2020.10.020_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jocn.2011.09.008","article-title":"Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease","volume":"19","author":"Cheshire","year":"2012","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.parkreldis.2020.10.020_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","article-title":"Buspirone in levodopa-induced dyskinesias","volume":"17","author":"Bonifati","year":"1994","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2020.10.020_bib14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/jnnp.54.4.376-a","article-title":"Buspirone in the treatment of levodopa induced dyskinesias","volume":"54","author":"Kleedorfer","year":"1991","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.10.020_bib15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00002826-198608000-00004","article-title":"Buspirone, Parkinson's disease, and the locus ceruleus","volume":"9","author":"Ludwig","year":"1986","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2020.10.020_bib16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/00002826-198612000-00007","article-title":"Buspirone in Parkinson's disease","volume":"9","author":"Hammerstad","year":"1986","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2020.10.020_bib17","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/mds.25919","article-title":"The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale","volume":"29","author":"Leentjens","year":"2014","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2020.10.020_bib18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.parkreldis.2020.10.020_bib19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0165-0327(88)90072-9","article-title":"The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders","volume":"14","author":"Maier","year":"1988","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.parkreldis.2020.10.020_bib20","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement disorder society UPDRS revision task force. Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.10.020_bib21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.parkreldis.2020.10.020_bib22","series-title":"ECDEU Assessment Manual for Psychopharmacology","year":"1976"},{"issue":"16","key":"10.1016\/j.parkreldis.2020.10.020_bib23","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/mds.22341","article-title":"The unified dyskinesia rating scale: presentation and clinimetric profile","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.10.020_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinic-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.10.020_bib25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jns.2014.07.002","article-title":"Freezing of gait in Chinese patients with Parkinson disease","volume":"345","author":"Ou","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2020.10.020_bib26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1176\/appi.neuropsych.17090177","article-title":"Anxiety independently contributes to severity of freezing of gait in people with Parkinson's disease","volume":"31","author":"Pimenta","year":"2019","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"issue":"7","key":"10.1016\/j.parkreldis.2020.10.020_bib27","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/mds.27417","article-title":"Evidence for subtypes of freezing of gait in Parkinson's disease","volume":"33","author":"Ehgoetz Martens","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.10.020_bib28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2169\/internalmedicine.1359-18","article-title":"Antidepressants for depression, apathy, and gait instability in Parkinson's disease: a multicenter randomized study","volume":"58","author":"Takahashi","year":"2019","journal-title":"Intern. Med."},{"key":"10.1016\/j.parkreldis.2020.10.020_bib29","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1161\/STROKEAHA.111.000031","article-title":"Novel methodological approaches to phase I, II, and III trials","volume":"44","author":"Yeatts","year":"2013","journal-title":"Stroke"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020308117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020308117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:19:44Z","timestamp":1761178784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802020308117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":29,"alternative-id":["S1353802020308117"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.10.020","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}